Advaxis's Cancer Immunotherapies Featured on FOX News

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advaxis's Cancer Immunotherapies Featured on FOX News

PRINCETON, N.J., Dec. 12, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a biotechnology company developing cancer immunotherapies, announced that its Lm -LLO immunotherapy technology is featured on FOX News Channel in a broadcast segment and article, entitled, "Teaching the immune system to fight back against cancer."

The segment and accompanying article can be accessed via the following URL:

http://www.foxnews.com/health/2014/12/10/teac...st-cancer/

The Fox News broadcast segment is reported by Dr. Manny Alvarez, FOX News Channel's Senior Managing Editor for Health News. Dr. Alvarez is the Chairman of the Department of Obstetrics and Gynecology and Reproductive Science at Hackensack University Medical Center in New Jersey, and is Adjunct Professor of Obstetrics and Gynecology at New York University School of Medicine in New York City.

The Fox News article, by Lindsay Carlton, features a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and surgery to remove their tumors.

Dr. Brett A. Miles, Assistant Professor of Otolaryngology at the Icahn School of Medicine at Mount Sinai Hospital, and lead investigator of the ongoing Phase 1/2 "window of opportunity" study told Fox News that the early data looks promising and that they have seen some immune response to the tumors.

Dr. Miles continued, "The exciting thing about immunotherapy is that traditional therapies like radiation treat at the point of time, but they don't offer any long-lasting benefits for these types of cancers. Immunotherapy has a long-lasting benefit because the idea is to make sure the patient's immune system is aware of these potentially circulating tumor cells."

The Fox News story also features Advaxis's scientific founder, Yvonne Paterson, Ph.D., Professor of Microbiology at the Perelman School of Medicine and Associate Dean for Research and Professor with the University Of Pennsylvania School Of Nursing. In the segment, Dr. Paterson shares how her discovery of the Lm -LLO immunotherapy platform was driven by her own diagnosis with breast cancer, as well the loss of her father and sister-in-law to colon cancer and ovarian cancer, respectively.

The story also interviews Nicola Mason, Assistant Professor of Medicine and Pathobiology at the University of Pennsylvania, and the principal investigator of two clinical trials evaluating ADXS-cHER2 in dogs diagnosed with osteosarcoma (bone cancer) to determine if the therapy can improve overall survival and prevent metastatic disease.

While discussing the data in pet dogs with Fox News , Dr. Mason stated, "We are actually prolonging survival of these dogs in some cases out to two-and-a-half years plus— and these dogs do not have evidence of clinical disease at this time, so they appear to be tumor free, which is remarkable."

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm -LLO platform technology. The Lm -LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead Lm -LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis's ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.

Advaxis's second Lm -LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. ("Merck"), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm -LLO cancer immunotherapy, ADXS-PSA, with Merck's PD-1 checkpoint inhibitor KEYTRUDA ® (pembrolizumab). The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.

Advaxis is also developing Lm -LLO immunotherapy ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS-cHER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers and to conduct a clinical program in pediatric osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.

For more information please visit www.advaxis.com .

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov . Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

KEYTRUDA is a registered trademark of Merck & Co., Inc.

Company: Advaxis, Inc. Greg Mayes, Executive Vice President and COO 609.452.9813 ext. 102 Media Contact: Tiberend Strategic Advisors, Inc. Amy S. Wheeler 646.362.5750

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 105

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 65

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 46

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
TSA at 25: Security Mission Meets a Tough Travel Reality

Updated Category News Views 104

Twenty-five years after its birth from catastrophe, TSA is still carrying a job nobody should take lightly. The agency marked its anniversary on November 19, 2026, looking back to the September 11, 2001 attacks that led to federalized aviation screening and a permanent reshaping of how Americans move through airports. This is not the sort of milestone that deserves...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 44

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading
Highway 99 Truck Death Puts Safety Records in Focus

Updated Category News Views 97

A stopped car on a highway shoulder is supposed to be a bad day, not a death sentence. Yet on November 5, 2026, a person helping a relative with a disabled vehicle was killed on northbound Highway 99 in Elk Grove after a commercial tractor-trailer allegedly drifted onto the shoulder, hit both stationary vehicles, and overturned. Northbound lanes were closed for hours. A...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 109

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 102

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 146

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Pickleman’s Chips Turn a Side Into a Brand Signal Now

Updated Category News Views 79

A bag of dill pickle chips is hardly earthshaking news, yet this one says plenty about where fast-casual brands are trying to compete. Pickleman’s Gourmet Cafe is launching its own proprietary chip line with non-GMO ingredients, sunflower oil, a pared-down ingredient profile, and a flavor that actually fits the name on the door. More importantly, a portion of each...

Continue Reading

Top 5 Most Recently Viewed Articles

FRNT Financial Expands Its Investment Portfolio with BTC

Updated Category News Views 101

FRNT Financial's New Bitcoin Acquisition FRNT Financial Inc. has made headlines with the recent purchase of 3.14 BTC (Bitcoin), which totals an impressive C$500,000, roughly equivalent to US$115,594 per BTC. This acquisition highlights the company’s robust strategy to widen its investment horizons by venturing into digital assets, showcasing their keen understanding of...

Continue Reading
Pasinex Reports Q2 2025 Results with Key Developments Ahead

Updated Category News Views 143

Pasinex Resources Limited Financial Highlights Pasinex Resources Limited (CSE: PSE) has released its financial results for the second quarter ended June 30, 2025. The company’s latest earnings report highlights both challenges and strategic advancements as it aims for growth in the zinc market. Quarterly Performance Overview In Q2 2025, Pasinex reported a net loss of...

Continue Reading
Join the Class Action Against Perpetua Resources Corp. Today

Updated Category News Views 201

Understanding the Class Action Against Perpetua Resources Corp. In recent developments, a significant class action lawsuit has been initiated on behalf of investors in Perpetua Resources Corp. (NASDAQ: PPTA). This lawsuit arises from allegations that the company misrepresented critical information regarding the Stibnite Gold Project, leading to substantial financial...

Continue Reading
Celebrating Excellence: 2026 ACGME International Award Recipients

Updated Category News Views 304

Celebrating the 2026 ACGME International Awards In a significant announcement that highlights dedication to global medical education, ACGME International (ACGME-I) celebrates the recipients of the 2026 ACGME International Awards. These awards recognize exceptional individuals within institutions accredited by ACGME-I, shining a light on their commitment to enhancing...

Continue Reading
APTIM Achieves Top 10 Ranking in Environmental Management Again

Updated Category News Views 79

APTIM Maintains Stellar Position in Environmental Rankings In an impressive feat for the fourth consecutive year, APTIM has been celebrated in the Top 10 Environmental Management Firms according to a prestigious ranking by Engineering News-Record (ENR). This year, APTIM proudly holds the seventh position in environmental management and tenth in the nuclear waste category....

Continue Reading